Arrowhead Q2 Call: No New Disclosures, Thesis on Hold

What happened

Arrowhead's Q2 2026 earnings call provided no new material disclosures on REDEMPLO net sales or sHTG timeline, as management reiterated prior guidance. The company continues to report revenue primarily from collaborations, with product sales still not disclosed, keeping the launch proof point pending. Management likely reaffirmed the Q3 2026 sHTG top-line and year-end sNDA intent, but without concrete sales numbers, the valuation anchor remains on future catalysts. The stock, at $63.82, already prices in a successful transition, leaving limited upside without demonstrated commercial traction. Investors should remain on the sidelines until either net sales emerge or the sHTG data provides a clearer catalyst path.

Implication

The thesis hinges on REDEMPLO net sales materializing and sHTG Phase 3 success. Until net sales are disclosed, the stock lacks a margin of safety. The earnings call provided no catalyst to change the WAIT rating. Investors should monitor for payer coverage updates and prescription persistence. A better entry point below $55 offers improved risk/reward.

Thesis delta

The Q2 call introduced no new information that alters the base-case expectations; the thesis remains dependent on upcoming sHTG data and REDEMPLO revenue disclosure.